# Beam Therapeutics Inc.: Form 10-Q for the period ended Jun 30, 2022

- Company: [Beam Therapeutics Inc.](/companies/beam.md) (CIK 1745999)
- Form: 10-Q
- Filed: 2022-08-09
- Accepted by EDGAR: Aug 9, 2022, 07:31 ET
- Period: 2022-06-30
- Accession: 0000950170-22-015755
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1745999/000095017022015755/beam-20220630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1745999/000095017022015755/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-04-01 to 2022-06-30 | $16.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2022-01-01 to 2022-06-30 | $25.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months, 2022-04-01 to 2022-06-30 | $74.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2022-01-01 to 2022-06-30 | $140.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2022-04-01 to 2022-06-30 | −$82.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2022-01-01 to 2022-06-30 | −$158.2m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2022-04-01 to 2022-06-30 | −$72.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2022-01-01 to 2022-06-30 | −$141.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-04-01 to 2022-06-30 | −$1.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2022-01-01 to 2022-06-30 | −$2.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-04-01 to 2022-06-30 | −$1.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2022-01-01 to 2022-06-30 | −$2.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-04-01 to 2022-06-30 | 70,210,227 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2022-01-01 to 2022-06-30 | 69,461,207 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2022-01-01 to 2022-06-30 | $166.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2022-01-01 to 2022-06-30 | $28.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-06-30 | $265.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-06-30 | $1.18bn | us-gaap:AssetsCurrent |
| Total assets | at 2022-06-30 | $1.42bn | us-gaap:Assets |
| Current liabilities | at 2022-06-30 | $212.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-06-30 | $618.2m | us-gaap:Liabilities |
| Shareholders' equity | at 2022-06-30 | $800.2m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1745999/000095017022015755/beam-20220630.htm

Filed Aug 9, 2022.
Source: SEC EDGAR, the filing index for accession 0000950170-22-015755. Last ingested by Listed: Nov 14, 2026, 12:58 ET. No prices; not investment advice.
